{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:46Z","timestamp":1793317606025,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG078759"],"award-info":[{"award-number":["R01AG078759"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00198-025-07668-x","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:32:52Z","timestamp":1761568372000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8010-4296","authenticated-orcid":false,"given":"Selvam R.","family":"Sendhil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulbh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Oganisian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Adegboye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleen N.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"7668_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"7668_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/dhps.s7727","volume":"3","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf 3:79\u201391. https:\/\/doi.org\/10.2147\/dhps.s7727","journal-title":"Drug Healthc Patient Saf"},{"key":"7668_CR3","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","volume":"26","author":"S Ferrari","year":"2015","unstructured":"Ferrari S, Adachi JD, Lippuner K et al (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26:2763\u20132771. https:\/\/doi.org\/10.1007\/s00198-015-3179-x","journal-title":"Osteoporos Int"},{"issue":"5","key":"7668_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051140","volume":"10","author":"KN Hayes","year":"2021","unstructured":"Hayes KN, Winter EM, Cadarette SM, Burden AM (2021) Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med 10(5):1140. https:\/\/doi.org\/10.3390\/jcm10051140","journal-title":"J Clin Med"},{"key":"7668_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116925","volume":"177","author":"KR Cruchelow","year":"2023","unstructured":"Cruchelow KR, Peter ME, Chakrabarti A et al (2023) Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: a retrospective study of patients with osteoporosis in a real-world clinical setting. Bone 177:116925. https:\/\/doi.org\/10.1016\/j.bone.2023.116925","journal-title":"Bone"},{"issue":"2","key":"7668_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33(2):190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"7668_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100267","volume":"12","author":"AD Anastasilakis","year":"2020","unstructured":"Anastasilakis AD, Evangelatos G, Makras P, Iliopoulos A (2020) Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Rep 12:100267. https:\/\/doi.org\/10.1016\/j.bonr.2020.100267","journal-title":"Bone Rep"},{"key":"7668_CR8","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27:1917\u20131921. https:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"7668_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7668_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1475-6773.2010.01194.x","volume":"46","author":"O Intrator","year":"2011","unstructured":"Intrator O, Hiris J, Berg K, Miller SC, Mor V (2011) The residential history file: studying nursing home residents\u2019 long-term care histories. Health Serv Res 46(1):120\u2013137. https:\/\/doi.org\/10.1111\/j.1475-6773.2010.01194.x","journal-title":"Health Serv Res"},{"issue":"6","key":"7668_CR11","doi-asserted-by":"publisher","first-page":"ziaf061","DOI":"10.1093\/jbmrpl\/ziaf061","volume":"9","author":"KN Hayes","year":"2025","unstructured":"Hayes KN, Sendhil SR, Aggarwal S et al (2025) Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States. JBMR Plus 9(6):ziaf061. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf061","journal-title":"JBMR Plus"},{"key":"7668_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929\u20131930. https:\/\/doi.org\/10.1007\/s00198-015-3459-5","journal-title":"Osteoporos Int"},{"key":"7668_CR13","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925. https:\/\/doi.org\/10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"7668_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"16","key":"7668_CR15","doi-asserted-by":"publisher","first-page":"E485","DOI":"10.1503\/cmaj.180115","volume":"190","author":"C Symonds","year":"2018","unstructured":"Symonds C, Kline G (2018) Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ 190(16):E485\u2013E486. https:\/\/doi.org\/10.1503\/cmaj.180115","journal-title":"CMAJ"},{"key":"7668_CR16","unstructured":"Osteoporosis Canada (2018) Increased risk of vertebral fracture after stopping denosumab. https:\/\/osteoporosis.ca\/position-statements\/increased-risk-of-vertebral-fracture-after-stopping-denosumab\/. Accessed 11 Mar 2025"},{"issue":"7","key":"7668_CR17","doi-asserted-by":"publisher","first-page":"ziae046","DOI":"10.1093\/jbmrpl\/ziae046","volume":"8","author":"S Minisola","year":"2024","unstructured":"Minisola S (2024) Denosumab discontinuation: COVID-19 pandemic and beyond. JBMR Plus 8(7):ziae046. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae046","journal-title":"JBMR Plus"},{"issue":"5","key":"7668_CR18","doi-asserted-by":"publisher","first-page":"ziae027","DOI":"10.1093\/jbmrpl\/ziae027","volume":"8","author":"AM Rzepka","year":"2024","unstructured":"Rzepka AM, Cheung AM, Kim S, Gomes T, Cadarette SM (2024) On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal. JBMR Plus 8(5):ziae027. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae027","journal-title":"JBMR Plus"},{"issue":"2","key":"7668_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3803\/enm.2021.1369","volume":"37","author":"WL Tay","year":"2022","unstructured":"Tay WL, Tay D (2022) Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab (Seoul) 37(2):183\u2013194. https:\/\/doi.org\/10.3803\/enm.2021.1369","journal-title":"Endocrinol Metab (Seoul)"},{"key":"7668_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM (2023) Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos Int 34:573\u2013584. https:\/\/doi.org\/10.1007\/s00198-022-06648-9","journal-title":"Osteoporos Int"},{"key":"7668_CR21","unstructured":"Royal Australian College of General Practitioners (2024) Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgp-guidelines\/view-all-racgp-guidelines\/osteoporosis\/pharmacologic-approaches-to-prevention\/denosumab. Accessed 12 Jul 2025"},{"key":"7668_CR22","doi-asserted-by":"publisher","unstructured":"Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I (2020) Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone 130:115150. https:\/\/doi.org\/10.1016\/j.bone.2019.115150","DOI":"10.1016\/j.bone.2019.115150"},{"key":"7668_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117325","volume":"190","author":"M Martin-Perez","year":"2025","unstructured":"Martin-Perez M, Sanchez-Delgado B, Garcia-Poza P, Lopez-Alvarez S, Martin-Merino E (2025) Multiple vertebral fractures after antiosteoporotic medications discontinuation: a comparative study to evaluate the potential rebound effect of denosumab. Bone 190:117325. https:\/\/doi.org\/10.1016\/j.bone.2024.117325","journal-title":"Bone"},{"issue":"7","key":"7668_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/m20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu H, Yoshida K, Zhao SS et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis\u202f: a population-based cohort study. Ann Intern Med 173(7):516\u2013526. https:\/\/doi.org\/10.7326\/m20-0882","journal-title":"Ann Intern Med"},{"issue":"7","key":"7668_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36(7):1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"issue":"12","key":"7668_CR26","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"key":"7668_CR27","doi-asserted-by":"publisher","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O; The Swiss Denosumab Study Group (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","DOI":"10.1002\/jbmr.4335"},{"key":"7668_CR28","unstructured":"Osteoporosis Canada (2024) Should bone turnover markers be routinely monitored when discontinuing someone from denosumab? https:\/\/osteoporosis.ca\/position-statements\/should-bone-turnover-markers-be-routinely-monitored-when-discontinuing-someone-from-denosumab\/. Accessed 25 Jul 2025"},{"issue":"11","key":"7668_CR29","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM Extension trials additional post hoc analyses. J Bone Miner Res 37(11):2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Miner Res"},{"key":"7668_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.medntd.2021.100072","volume":"11","author":"B Osipov","year":"2021","unstructured":"Osipov B, Christiansen BA (2021) Mechanisms for increased systemic fracture risk after index fracture. Medicine in Novel Technology and Devices 11:100072. https:\/\/doi.org\/10.1016\/j.medntd.2021.100072","journal-title":"Medicine in Novel Technology and Devices"},{"key":"7668_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11657-019-0676-0","volume":"15","author":"R Niimi","year":"2020","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2020) Second rebound-associated vertebral fractures after denosumab discontinuation. Arch Osteoporos 15:7. https:\/\/doi.org\/10.1007\/s11657-019-0676-0","journal-title":"Arch Osteoporos"},{"key":"7668_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11657-022-01065-1","volume":"17","author":"A Zaman","year":"2022","unstructured":"Zaman A, Rothman MS, Billups SJ (2022) Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record. Arch Osteoporos 17:18. https:\/\/doi.org\/10.1007\/s11657-022-01065-1","journal-title":"Arch Osteoporos"},{"key":"7668_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07589-9","author":"MJ Bennett","year":"2025","unstructured":"Bennett MJ, Center JR, Carter S, Moles R, Perry L (2025) Implementing pharmacist-led home medicines reviews within fracture liaison services for better post-fracture care: a qualitative study of patient and practitioner experience. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07589-9","journal-title":"Osteoporos Int"},{"key":"7668_CR34","doi-asserted-by":"publisher","unstructured":"Hall SF, Edmonds SW, Lou Y et al (2017) Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) 57(4):503\u2013509. https:\/\/doi.org\/10.1016\/j.japh.2017.05.003","DOI":"10.1016\/j.japh.2017.05.003"},{"issue":"2","key":"7668_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3803\/enm.2023.1663","volume":"38","author":"C Jeong","year":"2023","unstructured":"Jeong C, Lee J, Kim J et al (2023) Persistence with denosumab in male osteoporosis patients: a real-world, non-interventional multicenter study. Endocrinol Metab (Seoul) 38(2):260\u2013268. https:\/\/doi.org\/10.3803\/enm.2023.1663","journal-title":"Endocrinol Metab (Seoul)"},{"key":"7668_CR36","doi-asserted-by":"crossref","unstructured":"Blanch J, Casado E, Gonz\u00e1les J et al (2016) Medical professionals\u2019 perceptions regarding therapeutic adherence in patients with osteoporosis. Rev Osteoporos Metab Miner 8(1):15\u201323.\u00a0https:\/\/scielo.isciii.es\/scielo.php?script=sci_arttext&pid=S1889-836X2016000100003&. Accessed 25 Jul 2025","DOI":"10.4321\/S1889-836X2016000100003"},{"key":"7668_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00198-009-1023-x","volume":"21","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Bessette L, Hill CD et al (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837\u2013846. https:\/\/doi.org\/10.1007\/s00198-009-1023-x","journal-title":"Osteoporos Int"},{"key":"7668_CR38","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00198-025-07484-3","volume":"36","author":"KN Hayes","year":"2025","unstructured":"Hayes KN, Zullo AR, Berry SD et al (2025) Osteoporosis medication use over time in the United States and Canada. Osteoporos Int 36:1089\u20131094. https:\/\/doi.org\/10.1007\/s00198-025-07484-3","journal-title":"Osteoporos Int"},{"key":"7668_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","volume":"35","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Tsai JN, Lee H et al (2024) The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial. Osteoporos Int 35:255\u2013263. https:\/\/doi.org\/10.1007\/s00198-023-06932-2","journal-title":"Osteoporos Int"},{"key":"7668_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","volume":"33","author":"J Ha","year":"2022","unstructured":"Ha J, Kim J, Jeong C et al (2022) Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporos Int 33:1591\u20131599. https:\/\/doi.org\/10.1007\/s00198-022-06388-w","journal-title":"Osteoporos Int"},{"issue":"2","key":"7668_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2021) Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31(2):485\u2013492. https:\/\/doi.org\/10.1080\/14397595.2020.1769895","journal-title":"Mod Rheumatol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07668-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:37:38Z","timestamp":1769510258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07668-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7668"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07668-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"the supplemental file that was posted online reflects a tracked changes version instead of the clean version.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This study was approved by the Brown University Institutional Review Board, and the requirement for informed consent was waived (protocol #2022003400).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The National Institute on Aging had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"KNH has received investigator-initiated grant funding paid directly to Brown University for investigator-initiated research from Sanofi, Genentech, and GlaxoSmithKline for research on influenza vaccination in nursing homes, influenza outbreak control, and shingles vaccination in nursing homes, respectively. ARZ has received grant funding from Sanofi paid directly to Brown University for research unrelated to the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}